Kintara Therapeutics has received Orphan Drug Designation from the FDA for VAL-083 for the treatment of diffuse intrinsic pontine glioma – DIPG -, a rare and highly-aggressive childhood brain cancer.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on KTRA:
- Kintara Therapeutics Blasts Up after Children’s Brain Cancer Development
- Kintara Therapeutics’ treatment of DIPG receives FDA orphan designation
- Kintara Therapeutics regains compliance with Nasdaq listing rules
- Kintara Therapeutics Shares (NASDAQ: KTRA) Surge after Receiving Fast Track Designation
- Kintara Therapeutics grants FTD from FDA for REM-001
